Leucovorin prescriptions for autism increase amid evidence gaps, prompting discussion

Exploring off-label leucovorin use

Leucovorin, a form of folate also known as folinic acid, has seen increased prescribing for autism-related support needs despite limited efficacy evidence, Medical Xpress reported last month. The drug is FDA-approved for treating cerebral folate deficiency - a rare genetic condition - but the agency has clearly stated it is not approved as an autism support, CNN reported in March 2026.

This off-label use has grown through individual reports and small studies, including NCT02839915, a clinical trial involving 48 participants. While some families report positive experiences - like one child who increased communication after starting the medication, according to a 2025 case report - researchers emphasize these anecdotes don't replace rigorous evidence.

The FDA has acknowledged the need for more support options, taking action in 2025 to facilitate research.

Autistic self-advocates remind us that support approaches should respect neurodiversity. As one advocate told NeuroClastic, 'Medication decisions should center autistic experiences and needs, not just behavior modification.'

Current support options

Risperidone remains the only FDA-approved medication specifically for autism-related distress, as detailed in a 2026 Frontiers in Pharmacology review. No pharmacological options exist for core aspects of autistic experience like social communication styles or focused interests.

The FDA has acknowledged the need for more support options, taking action in 2025 to facilitate research. However, they've not endorsed any medications for core autistic characteristics.

Why the discussion matters

The leucovorin conversation reflects broader considerations in autism support: balancing the need for effective options with the risks of unproven approaches. While some clinicians see trying leucovorin as reasonable given limited alternatives, others caution against widespread use without Phase 3 trial data.

This situation presents complex decisions for families considering medications with uncertain benefits and potential effects - a challenge heightened by the diversity of autistic experiences and needs. As noted in a Cureus review, individual responses to medications vary significantly across the autism spectrum.